Idexx Labs (IDXX) Tops Q3 EPS by 1c; Raises FY11 Outlook; Guides FY12
Tweet
Share
E-mailGet Alerts IDXX Hot Sheet
Price: $570.58 -2.74%
Financial Fact:
Cost of service revenue: 97.67M
Today's EPS Names:
ITG, MTEX, NSYS, More
Financial Fact:
Cost of service revenue: 97.67M
Today's EPS Names:
ITG, MTEX, NSYS, More
Join SI Premium – FREE
Idexx Laboratories, Inc. (NASDAQ: IDXX) reported Q3 EPS of $0.66, $0.01 better than the analyst estimate of $0.65. Revenue for the quarter came in at $301 million versus the consensus estimate of $294.88 million.
Idexx Laboratories, Inc. sees FY2011 EPS of $2.71-$2.74, versus prior guidance of $2.68-$2.73 and the consensus of $2.72. Idexx Laboratories, Inc. sees FY2011 revenue of $1.215 billion, versus prior guidance of $1.205-$1.215 billion and the consensus of $1.21 billion.
Idexx Laboratories, Inc. sees FY2012 EPS of $3.00-$3.10, versus the consensus of $3.06. Idexx Laboratories, Inc. sees FY2012 revenue of $1.295-$1.315 billion, versus the consensus of $1.30 billion.
Idexx Laboratories, Inc. sees FY2011 EPS of $2.71-$2.74, versus prior guidance of $2.68-$2.73 and the consensus of $2.72. Idexx Laboratories, Inc. sees FY2011 revenue of $1.215 billion, versus prior guidance of $1.205-$1.215 billion and the consensus of $1.21 billion.
Idexx Laboratories, Inc. sees FY2012 EPS of $3.00-$3.10, versus the consensus of $3.06. Idexx Laboratories, Inc. sees FY2012 revenue of $1.295-$1.315 billion, versus the consensus of $1.30 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- IDEXX launches point-of-care cardiac test for cats and dogs
- Capstone Energy+, Inc. (CEPL) Reports Q2 Loss of $0.03
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
